Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

A medical oncologist called the late-stage clinical trial results “remarkable,” though Sasse said the drug means his body ...

Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.

A new pill could be the future of treatment late-stage pancreatic cancer in the U.S., nearly doubling the length patients ...

The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic ...

New experimental medications seem to extend survival with the hard-to-treat cancer.

In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...

A new drug that works by making tumors more susceptible to chemotherapy and the immune system has increased survival in those ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event hereOCALA, Fla., ...